癌症治疗所致心肌病:人诱导多能干细胞模型能否助力预防?
本文综述了常见化疗药物的心脏毒性特征,以及利用人诱导多能干细胞来源心肌细胞(hiPSC-CMs)在体外构建毒性模型的研究进展。文章指出,蒽环类等传统药物及酪氨酸激酶抑制剂、蛋白酶体抑制剂和免疫治疗均可引起多样心血管及代谢并发症,hiPSC-CM 化疗研究有望通过个体化医疗和更安全的药物开发改善癌症治疗。
要点
- 蒽环类、酪氨酸激酶抑制剂、蛋白酶体抑制剂和免疫治疗均可致多样心血管及代谢并发症。
- hiPSC-CMs 日益用于疾病建模、药物发现和机制性毒性研究。
- hiPSC-CM 化疗研究有望推动个体化医疗与更安全的药物开发。
核心结论
- 癌症治疗的心脏毒性可发生于治疗中及治疗完成后乃至癌症生存期,hiPSC-CM 模型有望助力预防与更安全药物开发。
研究设计与样本
- 综述:汇总常见化疗药物的心脏毒性特征及利用 hiPSC-CMs 进行体外建模的研究工作。
主要发现
- 蒽环类等传统药物的心脏毒性已较为明确。
- 酪氨酸激酶抑制剂、蛋白酶体抑制剂和免疫治疗也可引起多样心血管和代谢并发症。
- hiPSC-CM 化疗研究已取得有希望的结果。
临床怎么用
- 可将 hiPSC-CMs 用于化疗药物心脏毒性的机制研究与毒性筛选,服务个体化医疗和更安全药物开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiotoxic effects from cancer therapy are a major cause of morbidity during cancer treatment. Unexpected toxicity can occur during treatment and/or after completion of therapy, into the time of cancer survivorship. While older drugs such as anthracyclines have well-known cardiotoxic effects, newer drugs such as tyrosine kinase inhibitors, proteasome inhibitors, and immunotherapies also can cause diverse cardiovascular and metabolic complications. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are increasingly being used as instruments for disease modelling, drug discovery, and mechanistic toxicity studies. Promising results with hiPSC-CM chemotherapy studies are raising hopes for improving cancer therapies through personalized medicine and safer drug development. Here, we review the cardiotoxicity profiles of common chemotherapeutic agents as well as efforts to model them in vitro using hiPSC-CMs.
引用
- Stack JP, Moslehi J, Sayed N, et al. Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it? Eur Heart J. 2019. PMID: 29377985. doi:10.1093/eurheartj/ehx811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。